News and Announcements
Treatment of the First Patient in XanADu Marks Landmark in Alzheimer’s Disease Trial
- Published May 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical (ASX: ACW) is delighted to announce the treatment of the first patient in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease. This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University in Scotland and Actinogen Medical in Australia, to develop Xanamem as a promising new treatment for Alzheimer’s disease.
KEY TAKEAWAYS:
- Actinogen Medical reaches a major milestone with the first patient enrolled into XanADu – its Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
- The first trial patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia.
- This marks a defining moment in the development of Xanamem following more than a decade of research.
- Xanamem blocks excess production of cortisol, the stress hormone, in the brain and represents a promising new approach to treat Alzheimer’s disease.
- XanADu will enrol 174 patients at 20 research sites in the USA, the UK and Australia with the final patientexpected in Q4 2018 and top-line results in Q1 2019.
Alzheimer’s expert Professor Colin Masters, AO, Laureate Professor at The University of Melbourne, one of the AIBL study’s key authors and a member of Actinogen’s Scientific Advisory Board, said Xanamem could provide the turning-point needed in finding a new effective treatment for Alzheimer’s disease.
“Earlier this year, the AIBL study, a 1100+ participant, 9-year study published data showing that raised cortisol is strongly associated with the development of Alzheimer’s disease. Xanamem, through its inhibition of cortisol in the brain, could represent a major advance in the treatment of Alzheimer’s,” he said.
“I am delighted that Australia is at the forefront of global Alzheimer’s research in initiating the XanADu trial, evaluating Xanamem as a treatment for this devastating disease.”
Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
